Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
| Onpattro | patisiran | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
| Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | ||
| Onureg | azacitidine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | classical Hodgkin Lymphoma (cHL) after failure of ASCT | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | Nivolumab | Metastatic Hepatocellular Carcinoma (HCC) | Do not reimburse | Complete | ||
| Opdivo | Nivolumab | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 29, 2024